| Oyster Point Pharma, Inc. | |
| Type: | Subsidiary |
| Traded As: | NASDAQ: |
| Foundation: | 2015[1] |
| Location City: | Princeton, New Jersey |
| Location Country: | U.S. |
| Key People: | Jeffrey Nau (president and CEO) |
| Industry: | Biotechnology |
Oyster Point Pharma, Inc. is an American biopharmaceutical company based in Princeton, New Jersey, focusing on the development of pharmaceutical therapies to treat ophthalmic diseases.[2]
The lead product of the company is Tyrvaya. In October 2021, it was the first nasal spray approved by Food and Drug Administration to treat dry eye syndrome.[3]
Prior to going public, Oyster Point Pharma operated at a loss of $16.5 million in 2018.[4] In February 2019, still at clinical stage, the company raised $93 million in its Series B funding round.[5] [6]
In October 2019, the company issued 5-million shares in the initial public offering with NASDAQ Global Select Market at the price of $16 per share with the first trading day on October 31.[7] In January 2023 Viatris acquired Oyster Point Pharma in an all-cash deal.[8]